top of page
  • LinkedIn

David Fischer

Chief Technology Officer, Discovery

David holds a degree in Chemistry and a PhD in Molecular Genetics, both from Leiden University in The Netherlands.  After six years of post-doctoral fellowships at the Netherlands Institute for Neuroscience in Amsterdam and the Free University Amsterdam he joined Galapagos.


Charles River acquired the service operations from Galapagos in 2014 and David held Executive Director positions for Biology and DMPK and the wider Discovery operations, before becoming Chief Technology Officer for Discovery in 2022. 

As Chief Technology Officer for Discovery, David works with our drug discovery unit, as well as across other Charles River business units to help expedite our clients drug discovery and development programs. Furthermore, David works with our strategic partners to bring in cutting edge drug discovery platforms and technologies. In addition, collaborating with our CRL colleagues in pharmacology, safety assessment and CDMO on personalised (“n=1”) drug therapies, often for single patients with an ultra-rare disease.

bottom of page